Drug Search Results
More Filters [+]

JAB-30355

Alternative Names: JAB-30355, JAB 30355, JAB30355
Latest Update: 2024-08-05
Latest Update Note: Clinical Trial Update

Product Description

JAB-30355 is an orally bioavailable small molecule activator for the treatment of patients with solid tumors harboring P53 Y220C mutation. (Sourced from: https://www.jacobiopharma.com/en/news/Jacobio_Pharma_Receives_IND_Approval_for_P53_Y220C_Activator_JAB-30355_in_the_US)

Mechanisms of Action: p53 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jacobio
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JAB-30355

Countries in Clinic: China, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JAB-30355-1001

P2

Recruiting

Oncology Solid Tumor Unspecified

2027-01-01

Recent News Events

Date

Type

Title